Loxo Oncology (LOXO) Given Daily News Impact Rating of 0.14
News headlines about Loxo Oncology (NASDAQ:LOXO) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Loxo Oncology earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.0522591497986 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
LOXO has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating and set a $103.00 target price (up from $95.00) on shares of Loxo Oncology in a research report on Friday, October 6th. Zacks Investment Research downgraded Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. William Blair initiated coverage on Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating for the company. JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their target price for the company from $77.18 to $95.00 in a research report on Tuesday, November 14th. Finally, Citigroup cut their target price on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, November 16th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $90.57.
Shares of Loxo Oncology (NASDAQ:LOXO) opened at $90.47 on Friday. Loxo Oncology has a 1 year low of $36.75 and a 1 year high of $95.92. The firm has a market capitalization of $2,710.00, a price-to-earnings ratio of -15.57 and a beta of 2.54.
In related news, VP Jennifer Burstein sold 1,500 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $87.50, for a total transaction of $131,250.00. Following the completion of the sale, the vice president now directly owns 1,500 shares in the company, valued at approximately $131,250. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Naarden Jacob Van sold 1,541 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $86.52, for a total value of $133,327.32. Following the sale, the insider now owns 1,541 shares of the company’s stock, valued at $133,327.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,629,137 shares of company stock valued at $125,844,206. 44.40% of the stock is owned by corporate insiders.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.